Navigation Links
FDA Accepts Immucor's Response to Warning Letter
Date:6/6/2008

NORCROSS, Ga., June 6 /PRNewswire-FirstCall/ -- Immucor, Inc., (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced that today the FDA notified the company that it has reviewed Immucor's response to the previously-reported warning letter, and Immucor's proposed corrective actions appear to be adequate. The FDA stated it would evaluate the implementation and effectiveness of those corrective actions, as well as Immucor's overall compliance, at its next inspection.

The warning letter, which related to Immucor's internal quality system, was dated May 2, 2008, and the company responded on May 22, 2008, detailing the corrective actions it proposed to take.

Immucor CEO Dr. Gioacchino De Chirico said: "We take our regulatory responsibilities very seriously and worked diligently to respond to the FDA. We are pleased the FDA accepted our action plan, and was willing to move as quickly as it did. We have already begun implementing the plan."

Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of our market segments.

For more information on Immucor, please visit our website at http://www.immucor.com .

Statements contained in this press release that are not statements of historical fact are "forward-looking statements" as that term is defined under federal securities laws, including, without limitation, all statements concerning Immucor's expectations, beliefs, intentions or strategies for the future. Forward-looking statements may be identified by words such as "plans," "expects," "believes," "anticipates," "estimates," "projects," "may," "will,
'/>"/>

SOURCE Immucor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
2. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
3. Imaging Diagnostic Systems Accepts Resignations of Outside Directors
4. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
5. FDA Accepts Ranexa(R) sNDA and NDA for Filing
6. FDA Accepts Sucampos sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
7. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
8. Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkins Lymphoma
9. Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial
10. MannKind Corporation Response to Recent Market Events
11. Sanofi Pasteur Mounts Emergency Response to Yellow Fever Epidemic in Latin America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sep. 02, 2015 ... the addition of Jain PharmaBiotech,s new report ... to their offering. This report briefly ... sequencing technologies, and their applications. Current large and ... developing them. Various applications of sequencing are described ...
(Date:9/2/2015)... Research and Markets ( ... new report "Gene Therapy - Technologies, Markets and ... for gene therapy are difficult to estimate as there ... is marketed in China since ... 2014-2024. The estimates are based on epidemiology of diseases ...
(Date:9/2/2015)... CUMBERLAND, R.I. , Sept. 2, 2015 /PRNewswire/ ... has been enrolled in the multicenter Phase 2 ... for the long-term treatment of recurrent subfoveal choroidal ... AMD).  NT-503 is a unique vascular endothelial growth ... versatile ECT implant. "This landmark proof-of-concept ...
(Date:9/2/2015)... 2015 BioLight Life Sciences ... "Company"), a firm that invests in, manages and ... announced today that presentations highlighting its IOPtiMate™ system ... at the Ophthalmology Futures European Forum and the ... & Refractive Surgeons ("ESCRS"), both taking place in ...
Breaking Biology Technology:Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... YORK, April 7, 2008 Medicsight PLC, a,subsidiary ... ), and an industry,leader in the development of ... in the early detection and diagnosis of,disease, announces ... the,world,s leading medical imaging and picture archiving and ...
... 2008 Ardea Biosciences,Inc. (Nasdaq: RDEA ) ... its,second generation non-nucleoside reverse transcriptase inhibitors (NNRTIs),at the ... on two of the Company,s mitogen-activated ERK kinase,(MEK) ... the American,Association for Cancer Research (AACR) annual meeting., ...
... 2008 Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) ... Agreement with Open Monoclonal Technologies (OMT), a private,company ... Sangamo will,provide a non-exclusive, worldwide license to OMT ... Sangamo,s proprietary zinc finger,DNA-binding protein (ZFP) technology. OMT ...
Cached Biology Technology:Medicsight Announces New Marketing Partnership with INFINITT 2Medicsight Announces New Marketing Partnership with INFINITT 3Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences 2Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences 3Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals 2Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals 3
(Date:8/12/2015)... SPRINGS, Florida , August 12, 2015 ... the pace of mobile payment innovation and advanced biometrics ... to replace the way consumers rely on using their ... ahead with reinventing the future for payment services led ... (NASDAQ: NXTD ), :  Google, Inc. (NASDAQ: ...
(Date:8/11/2015)... August 11, 2015 Today, ZUK announced its ... as well as expected revenues in 2015 that relate to sales ... revenue guidance of approximately 2,200 MSEK for 2015. Jörgen ... prominent smartphone manufacturer in China ... selected FPC1 155 for Z1 ...
(Date:8/6/2015)... 2015  Today, U.S. Congressman Mike Honda ... to learn firsthand how Silicon Valley technologies can ... a world leader in multi-factor identity management and ... federal agencies and commercial organizations achieve new levels ... "The vast majority of network breaches can be ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Rep. Honda to Visit Crossmatch in Redwood City 2
... Shakespeare. In humans, nature may be less than half of ... researchers has found. In the first study of its ... explain why human birds of a feather flock together, but ... upon the social environment in which individuals interact with one ...
... Stanford University scientists have built the first solar cell made ... used in photovoltaic devices today. The results are ... ACS Nano . "Carbon has the potential to ... author Zhenan Bao, a professor of chemical engineering at Stanford. ...
... stem cells such as regenerating damaged tissues or organs ... past decade. While these types of applications are exciting, it ... immediate impact of stem cells on human health will most ... drugs. , The ability to generate stem cells by reprogramming ...
Cached Biology News:Social factors trump genetic forces in forging friendships, CU-led study finds 2Stanford scientists build the first all-carbon solar cell 2Stanford scientists build the first all-carbon solar cell 3The role of stem cells in developing new drugs 2
Cyan Standard is 7-hydroxy-4-trifluoromethylcoumarin...
Endothelin-converting enzyme 1 (EC 3.4.24.71) (ECE-1). [Source:Uniprot/SWISSPROT;Acc:P42892] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Red Standard is sodium salt of resorufin....
Oligodendrocyte Marker O1 MAb (Clone O1)...
Biology Products: